Previous studies demonstrated that SRGN is mainly involved in immune response, such as promoting the TNFα secretion from macrophages, and inhibiting classical and non-classical complement activation pathways.8 This implies that SRGN may have an important role in tumor immune escape, which may diminish the effect of antibody-dependent complement killing of the current tumor targeted therapy. This evidence concerns the gene TNF and neoplasm.